Sökning: "atenolol"
Visar resultat 1 - 5 av 15 avhandlingar innehållade ordet atenolol.
1. Pharmacogenomics of Antihypertensive Treatment & Clinical Pharmacological Studies of Digoxin Treatment
Sammanfattning : In Part I we found that the CYP2C9 genotype appears to influence the diastolic blood pressure response to the angiotensin II-receptor antagonist irbesartan in patients with hypertension and left ventricular hypertrophy. Those with the *1/*2 genotype (slower metabolism) responded better than those with the *1/*1 genotype (normal metabolism), likely due to a slower elimination of the drug. LÄS MER
2. Diastolic heart function in hypertension-induced left ventricular hypertrophy
Sammanfattning : Hypertensive left ventricular (LV) hypertrophy is an independent strong risk factor for cardiovascular morbidity and mortality. An abnormal diastolic relaxation in the absence of systolic impairment is often seen in patients with hypertension, whether LV hypertrophy is present or not. LÄS MER
3. Microarray Technology for Genotyping in Pharmacogenetics
Sammanfattning : The studies in this thesis describe the development of a microarray based minisequencing system and its application to highly parallel genotyping of single nucleotide polymorphisms. The technical developments included identification of a three-dimensional microarray surface coating with high binding capacity for oligonucleotides modified with amino groups as the most optimal one for the system. LÄS MER
4. Antihypertensive treatment and endothelial vasodilatory function
Sammanfattning : The endothelium integrates vascular tone by the synthesis of vasoactive substances secreted abluminally to the underlying vascular smooth muscle. Endothelial function has previously been shown to be impaired in primary, secondary and experimental forms of hypertension. LÄS MER
5. Cardiac electrophysiologic effects of mental stress
Sammanfattning : Background: Mental stress may trigger serious arrhythmias. Mental stress tests cause significant increases in heart rate, blood pressure and cardiac output. When beta-adrenergic inhibition is considered for secondary antiarrhythmic prophylaxis beta1 selective agents are often preferred because of less adverse reactions. LÄS MER